Promising Study Finds Nerivio Helps U.S. Veterans Skip Migraine Medications

Largest Real-World Study on Migraine Treatment in Veterans

The recent study published in Military Medicine marks a pivotal moment for migraine treatment among U.S. veterans. Conducted by Theranica, a company specializing in neuromodulation therapeutics, the research evaluates the efficacy of Nerivio, a groundbreaking wearable device that utilizes Remote Electrical Neuromodulation (REN) technology for managing migraines.

Study Overview

This extensive study is the most comprehensive real-world evidence assessment of its kind involving veterans. Over a period from November 2020 to February 2026, 466 veterans were engaged, and they underwent a total of 28,274 treatments utilizing the Nerivio device. The findings challenge traditional paradigms of migraine care and underscore the potential of non-pharmacologic methods, especially for individuals facing multiple health challenges due to military service.

The study co-authored by prominent neurologists from various Veterans Health Administration (VHA) centers, highlighted that approximately 77% of treatments allowed veterans to avoid prescribed medication altogether, either by using Nerivio alone or in conjunction with over-the-counter medications.

Key Findings

1. Efficacy of Treatment: Among the participants, 66.7% achieved pain relief two hours post-treatment, while 26.6% reported complete relief. Regarding functional disability, 69.3% experienced significant improvement, and 33.3% found complete freedom from disability.
2. Symptom Relief: Participants reported a 56.5% success rate in alleviating common migraine-associated symptoms such as sensitivity to light, noise, and nausea.
3. Timing of Treatment: One notable insight was that those who began treatment within one hour of migraine onset reported greater relief. In fact, timely treatment correlates with up to 28% improved disability relief and a doubling of the chances for complete freedom from functional disability.
4. Safety Profile: The safety of the device is impressive; adverse events were minimal, with only 0.4% of patients reporting mild, localized issues related to the device.

Significance and Expert Opinions

Dr. David Shulkin, former U.S. Secretary of Veterans Affairs, emphasizes the importance of this study, noting it supports non-pharmacological approaches for managing migraines, particularly for veterans facing polypharmacy due to multiple health issues. Alon Ironi, CEO of Theranica, points out that the accessibility of Narivio without requiring a neurologist's appointment greatly benefits patients desperately needing relief.

The integral relationship between migraine disorders and other service-related issues—such as PTSD and chronic pain—makes this successful alternative approach especially fitting within veteran care.

Dr. Alan R. Towne, a neurologist involved in the study, echoed this sentiment, highlighting the effective results veterans experienced with the device, reducing their reliance on conventional medication.

Future Directions

As Theranica positions Nerivio within U.S. veteran healthcare, the trial’s findings bolster the case for ensuring availability of non-drug therapy for migraine management. The success of this study accentuates Theranica’s mission to expand its offerings beyond migraines to other chronic pain conditions using REN technology.

The overarching conclusion is clear: Nerivio not only offers a safe and effective alternative for acute migraine relief but stands as a promising step towards enhancing the overall quality of care for veterans.

About Nerivio

Nerivio is recognized as the first FDA-cleared wearable that delivers Remote Electrical Neuromodulation therapy for both acute and preventive migraine treatment. Supported by extensive peer-reviewed clinical evidence, this non-invasive device has shown efficacy without the side effects commonly associated with traditional medication, presenting itself as a vital resource for effective migraine management among U.S. veterans.